Texas MPN Workshop 2021 | State-of-the-art developments in MPNs
Laura Michaelis
• 13 Aug 2021
Laura Michaelis, MD, Medical College of Wisconsin, Milwaukee, WI, shares cutting-edge developments in the field of myeloproliferative neoplasms (MPNs). Dr Michaelis discusses risk stratification and how increased research into the genetics and the molecular underpinnings of MPNs may improve outcomes, especially for high-risk patients. Dr Michaelis further talks on the role of ruxolitinib before stem cell transplantation, the importance of optimizing therapy timing, and on novel agents being developed as alternatives to JAK inhibitors and how these are being investigated in ongoing clinical trials using combinatorial approaches. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
